Colinz Laboratories Limited announced the passing of its Founder Director, Dr. Mani L.S., on November 7, 2025. Dr. Mani, who served as the Company Secretary and Compliance Officer, was described as a guiding force and principal architect behind the company's vision and values.

Key Details of the Announcement

Dr. Mani L.S. held the position of Director (non-Executive) and was a member of all Board Committees. His roles and committee memberships ceased effective November 7, 2025.

Company's Response and Next Steps

Colinz Laboratories expressed deep sorrow over the loss, acknowledging Dr. Mani's significant contributions to the company. The Board of Directors and employees conveyed their condolences to his family.

In light of this development, the company has outlined the following actions:

1. Immediate Measures: Colinz is taking steps to identify and appoint a qualified Company Secretary to fill the vacancy of Compliance Officer.

2. Interim Arrangement: Mr. Ganesh Chitte, the Chief Financial Officer, will oversee compliance and regulatory functions to ensure continued adherence to all applicable requirements.

The company has informed the Bombay Stock Exchange of these changes, as per regulatory requirements.

About Colinz Laboratories Limited

Colinz Laboratories Limited is identified by the ISIN code INE923C01011. The company's corporate office is located in Mumbai, indicating its presence in the Indian pharmaceutical or laboratory sector.

This announcement marks a significant transition for Colinz Laboratories, as it navigates the loss of a key founding member while ensuring continuity in its operations and compliance functions.

Colinz Laboratories Limited , a pharmaceutical formulations manufacturer, has announced its unaudited financial results for the second quarter and half-year ended September 30, 2025. The company's performance shows mixed results with a decrease in revenue but an increase in profitability.

Financial Highlights

Quarterly Performance

Colinz Laboratories experienced a decline in revenue from operations for the quarter ended September 30, 2025. The company reported revenue of ₹138.80 lakhs, down from ₹156.61 lakhs in the previous quarter. Despite the revenue dip, the company managed to improve its bottom line, with net profit increasing to ₹14.05 lakhs from ₹11.92 lakhs in the prior quarter.

Half-Year Results

For the half-year period, Colinz Laboratories posted revenue from operations of ₹295.41 lakhs. The net profit for the same period stood at ₹25.97 lakhs, indicating a positive trend in the company's profitability.

Balance Sheet Strength

The company's financial position appears to be stable. As of September 30, 2025, Colinz Laboratories reported total assets of ₹1,212.62 lakhs, showing an increase from ₹1,181.74 lakhs recorded in March 2025. Notably, the company maintains a strong liquidity position with cash and cash equivalents of ₹742.18 lakhs.

Corporate Governance

The financial results were reviewed by the audit committee and subsequently approved by the board of directors. Vora Associates, the statutory auditors of the company, issued an unqualified review report on the financial statements, providing assurance on the accuracy of the reported figures.

Conclusion

While Colinz Laboratories faced a quarter-on-quarter revenue decline, the improvement in net profit suggests effective cost management. The company's strong cash position and growing asset base indicate financial stability, which could support future growth initiatives in the pharmaceutical sector.